John  Stark, VIII net worth and biography

John Stark, VIII Biography and Net Worth

CEO of Quantum-Si
John Stark has served as Quantum-Si’s Chief Executive Officer since November 2020. Prior to joining Quantum-Si, Mr. Stark served as Chief Executive Officer of Celsee, Inc., a single cell analysis solutions provider, from January 2018 to April 2020, when Celsee, Inc. was acquired by Bio-Rad Laboratories, Inc. Mr. Stark previously served as Senior Vice President, Global Commercial Operations, Applied Markets of Fluidigm Corporation, a biotechnology tools provider, from October 2015 to October 2017. Before that, he served as Vice President, Clinical and Applied Markets at Life Technologies Corporation, a global biotechnology company, from October 2011 to October 2015. He also previously served as Senior Director of Sales at Pacific Biosciences of California, Inc., a provider of sequencing platforms, from September 2009 to September 2011, and as District Manager, East Region Industrial Sales, of Affymetrix, Inc., a provider of cellular and genetic analysis products, from April 2001 to January 2007. Mr. Stark earned his M.S. in Bioengineering from Arizona State University. Mr. Stark’s qualifications to serve on the board of directors of New Quantum-Si include his leadership experience in the healthcare industry, as well as his knowledge of Quantum-Si’s business.

How do I contact John Stark, VIII?

The corporate mailing address for Mr. Stark, VIII and other Quantum-Si executives is 452 FIFTH AVENUE 21ST FLOOR, NEW YORK NY, 10018. Quantum-Si can also be reached via phone at 866-688-7374 and via email at [email protected]. Learn More on John Stark, VIII's contact information.

Has John Stark, VIII been buying or selling shares of Quantum-Si?

John Stark, VIII has not been actively trading shares of Quantum-Si during the past quarter. Most recently, John Viii Stark sold 172,167 shares of the business's stock in a transaction on Monday, January 10th. The shares were sold at an average price of $5.86, for a transaction totalling $1,008,898.62. Learn More on John Stark, VIII's trading history.

Who are Quantum-Si's active insiders?

Quantum-Si's insider roster includes Christian LaPointe (General Counsel), and John Stark, VIII (CEO). Learn More on Quantum-Si's active insiders.

Are insiders buying or selling shares of Quantum-Si?

In the last year, Quantum-Si insiders bought shares 3 times. They purchased a total of 85,000 shares worth more than $141,900.00. The most recent insider tranaction occured on March, 15th when General Counsel Christian Lapointe bought 10,000 shares worth more than $17,400.00. Insiders at Quantum-Si own 30.0% of the company. Learn More about insider trades at Quantum-Si.

Information on this page was last updated on 3/15/2024.

John Stark, VIII Insider Trading History at Quantum-Si

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/10/2022Sell172,167$5.86$1,008,898.62View SEC Filing Icon  
See Full Table

John Stark, VIII Buying and Selling Activity at Quantum-Si

This chart shows John Viii Stark's buying and selling at Quantum-Si by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Quantum-Si Company Overview

Quantum-Si logo
Quantum-Si incorporated, a life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS). The company's platform is comprised of the Platinum NGPS instrument; the Platinum Analysis Software service; and reagent kits and semiconductor chips for use with its instruments. It is used in protein identification, protein variants, antibody characterization, biomarker identification, and post translational modification analysis applications. The company was founded in 2013 is headquartered in Branford, Connecticut.
Read More

Today's Range

Now: $1.64
Low: $1.61
High: $1.67

50 Day Range

MA: $1.77
Low: $1.51
High: $2.23

2 Week Range

Now: $1.64
Low: $1.12
High: $3.90

Volume

239,787 shs

Average Volume

719,425 shs

Market Capitalization

$233.20 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.04